Seminars in Oncology
Volume 34 , Pages S21-S28 , December 2007

Mycosis Fungoides: Pathophysiology and Emerging Therapies

  • Madeleine Duvic

      Affiliations

    • Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX.
    • Corresponding Author InformationAddress reprint requests to Madeleine Duvic, MD, Professor of Internal Medicine and Dermatology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. #434, Houston, TX 77030
    • Dr Duvic has received research grant support from Merck, Ligand, Gloucester, Curagen, Biogen, BioCryst, Yaupon, Cyclacel, Celgene, Novartis, and Allos. She has received honoraria from Merck, Ligand, and Novartis.
    • ,
  • Francine M. Foss

      Affiliations

    • Yale Cancer Center, New Haven, CT.

References 

  1. Lamberg SI, Bunn PA. Proceeding of the workshop on cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndromes). Cancer Treat Rep. 1979;63:561–564
  2. National Institutes of Health, National Cancer Institute. Mycosis Fungoides and the Sézary Syndrome Treatment. Available at: http://www.nci.nih.gov/cancertopics/pdq/treatment/mycosisfungoides/HealthProfessional/page3(accessed March 5, 2007)
  3. Alibert JLM. Description des maladies de la peau observees a l’hôpital St Louis. Barrois L’aine et Fils. 1806;1:413–446
  4. Bazin PAE: Maladies de la peau observees a l’hôpital St Louis, 1876.
  5. Willemze R, Jaffe ES, Berg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  6. Besnier E, Hallopeau H. On the erythrodermia of mycosis fungoides. J Cutan Genito Urin Dis. 1892;10:453
  7. Bunn PA, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep. 1979;63:725–728
  8. Schechter GP, Sausville EA, Fischmann AB, et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. Blood. 1987;69:841–849
  9. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;39:857–866
  10. Tan RS, Butterworth CM, McLaughlin H, et al. Mycosis fungoides: A disease of antigen persistence. Br J Dermatol. 1974;91:607–616
  11. Bromley SK, Burack KG, Johnson K, et al. The immunological synapse. Annu Rev Immunol. 2001;19:375–396
  12. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1089–1107
  13. Drummer R, Kohl O, Gillisson J, et al. Peripheral blood mononuclear cells in non-leukemic cutaneous-cell lymphoma patients: Reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation. Arch Dermatol. 1993;129:433–436
  14. Wood GS, Greenberg HL. Diagnosis, staging, and monitoring of cutaneous T-cell lymphoma. Dermatol Ther. 2003;16:269–275
  15. Xiao NL, Hazarika P, Zhang C, et al. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in Mycosis fungoides: A potential mechanism of tumor immune escape?. Clin Cancer Res. 2001;7:2682–2692
  16. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42:1014–1030
  17. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325–332
  18. Do JH, McLaughlin SS, Gaspari AA. Topical imiquimod therapy for cutaneous T-cell lymphoma. Skinmed. 2003;2:316–318
  19. Querfeld C, Lakshmi VN, Rosen ST, et al. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother. 2006;7:1–9
  20. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–39
  21. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003;101:4267–4272
  22. Kim YH, Duvic M, Obitz E. Clinical efficacy of zanolimumab (HuMax-CD4): Two phase II studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109:4655–4662
  23. O’Mahony D, Morris JC, Moses L, et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. Blood. 2005;106(suppl 1):937a;(abstr 3353)
  24. Forero-Torres A, Bernstein SH, Gopal A, et al. SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Blood. 2006;108:768a;(abstr 2718)
  25. Rook AH, Zaki MH, Wysocka M, et al. The role for interleukin-12 therapy of cutaneous T-cell lymphoma. Ann NY Acad Sci. 2001;941:177–184
  26. Rook AH, Wood GS, Yoo EK. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94:902–908
  27. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity with DAB(389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001;1:298–302
  28. Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126:575–583
  29. Edelson RL. Cutaneous T cell lymphoma: The helping hand of dendritic cells. Ann NY Acad Sci. 2001;941:1–11
  30. Drummer R. Emerging drugs in cutaneous T-cell lymphoma. Expert Opin Emerg Drugs. 2005;10:1–12
  31. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210–1216
  32. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer. 2001;1:194–202
  33. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood. 2001;98:2865–2868
  34. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125:1045–1052
  35. Olsen EA, Kim YH, Kuzel TM, et al. A phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115
  36. Piekarz RL, Frye R, Turner M, et al. Completion of the first cohort of patients with cutaneous T-cell lymphoma enrolled on a phase II trial of depsipeptide. Blood. 2005;106:71a;(abstr 231)
  37. Prince HM, George DJ, Johnstone R, et al. LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTLC): Changes in skin gene expression profiles related to clinical response following therapy. Proc Am Soc Clin Oncol. 2006;24:422s;(abstr 7501)
  38. Parks RE, Aggarwal RP. In:  Boyer PD editors. Ed 3. The Enzymes. vol 7:New York: Academic Press; 1972;p. 483–514
  39. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1:1010–1013
  40. Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3:45–81
  41. Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol. 2003;3:879–887
  42. Ni X, Zhang C, Talpur R, et al. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005;124:741–750
  43. Reed CJ. Apoptosis and cancer: strategies for integrating cell death. Semin Hematol. 2000;37:9–16
  44. Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Dis Dev. 2004;7:243–247
  45. Miles RW, Tyler PC, Furneaux RH, et al. One-third-the-sites transition-state inhibitors to purine nucleoside phosphorylase. Biochemistry. 1998;37:8615–8621
  46. Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—A novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1:1199–1210
  47. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase selectively inhibits human T lymphocytes. Proc Nat Acad Sci U S A. 2001;98:4593–4598
  48. Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol. 2003;3:879–887
  49. Bantia S, Miller PJ, Parker CD, et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: The role of dGTP in antiproliferative action of BCX-1777. Int Immunopharmacol. 2002;2:913–923
  50. Duvic M, Foss F, Olsen EA, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Blood. 2004;104:683a;(abstr 2491)
  51. Duvic M, Apisarnthanarax N, Cohen DS, et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;49:35–49
  52. Furman RR, Gandhi VV, Bennett JC, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood. 2004;104:750a;(abstr 2743)
  53. Furman RR, Iosava G, Isola L, et al. Forodesine (Fodosine), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase III study). Blood. 2005;106:259a;(abstr 881)
  54. Isola L, Furman RR, Gandhi V, et al. Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies. Blood. 2004;104:208b;(abstr 4501)
  55. Duvic M, Ziari S, Olsen EA, et al. Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol. 2004;22:613a;(abstr 6733)
  56. Duvic M, Forero-Torres A, Foss F, et al. Oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I/II study. Proc Am Soc Hematol. 2006;108:698a;(abstr 2467)

PII: S0093-7754(07)00225-4

doi: 10.1053/j.seminoncol.2007.11.006

Seminars in Oncology
Volume 34 , Pages S21-S28 , December 2007

Article Tools

* Image Usage & Resolution